01519nas a2200181   4500000000100000008004100001260003900042653005700081100001400138700001500152700001400167245012500181856008200306300001200388490000800400520090400408022002501312       2015                            d  bAmerican Public Health Association10aPublic Health, Environmental and Occupational Health1 aBailey TC1 aMerritt MW1 aTediosi F00aInvesting in Justice: Ethics, Evidence, and the Eradication Investment Cases for Lymphatic Filariasis and Onchocerciasis  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358176/pdf/AJPH.2014.302454.pdf  a629-6360 v1053 a<p>It has been suggested that initiatives to eradicate specific communicable diseases need to be informed by eradication investment cases to assess the feasibility, costs, and consequences of eradication compared with elimination or control. A methodological challenge of eradication investment cases is how to account for the ethical importance of the benefits, burdens, and distributions thereof that are salient in people’s experiences of the diseases and related interventions but are not assessed in traditional approaches to health and economic evaluation. We have offered a method of ethical analysis grounded in theories of social justice. We have described the method and its philosophical rationale and illustrated its use in application to eradication investment cases for lymphatic filariasis and onchocerciasis, 2 neglected tropical diseases that are candidates for eradication.</p>
  a0090-0036, 1541-0048